Krist’s decades of experience on the buy-side and sell-side of health and life sciences dealmaking spans the healthcare and life sciences landscape. He leads cross-disciplinary teams and delivers business-focused legal guidance to help clients pursue their most innovative strategies, working across borders and health and life sciences subsectors to connect and advise industry stakeholders. Krist is also skilled at developing creative transaction structures, conducting sector-specific due diligence, and providing forward-looking counsel to mitigate issues that can derail transactions or stunt long-term growth. His deep understanding of sector-specific regulatory nuances allows him to efficiently close transactions and maximize client outcomes.

Representative PE clients include Ampersand Capital Partners (buy-side and sell-side); Amulet Capital Partners (buy-side and sell-side); Windrose Health Investors (buy-side and sell-side M&A, and joint venture matters); Iron Path Capital (investments, carve-out acquisitions and new platform formations), Quad-C (new platform formation and investment and sell-side), PPC (buy-side).

Representative healthcare and life sciences companies include Baxter International and Vanda Pharmaceuticals (cross-border sales and acquisitions; licensing); REGENXBIO (strategic partnership with AbbVie); Cleveland Clinic, Hospital for Special Surgery and Northwestern Medicine (strategic innovation investments and joint ventures); numerous founder-owned businesses in strategic transactions with investors.

Show Less

• Baxter International in a wide variety of transactions, including the acquisition of a portfolio of hemostasis product lines from Mallinckrodt; multiple undisclosed acquisitions of liquid injectable pharmaceutical products; the acquisition of Chatham Therapeutics; strategic licenses with ScinoPharm Taiwan and Merrimack Pharmaceuticals; and acquiring the rights to manufacture and sell Scopoderm from GlaxoSmithKline
• Valinor Pharma and Healthcare Royalty Partners in the cross-border sale of US-based Valinor Pharma to German-based Grünenthal for a total deal value of approximately $250 million in upfront cash consideration
• Vanda Pharmaceuticals in the acquisition of US and Canadian rights to PONVORY (ponesimod) from Johnson & Johnson
• Enhanced Healthcare Partners in a range of transactions, including the sale of SCA Pharma to The Vistria Group and Excellere Partners; the formation and acquisition of Eventus WholeHealth Management; and the merger of Prospira PainCare with National Spine and Pain
• Iron Path Capital in its investments in Emergence Health, Capitol Pain Institute, Versant Diagnostics, and the formation of PureTech Scientific through the carve-out acquisition of the glycolic acid business from The Chemours Company
• Chicago Pacific Founders in its investment in Pinnacle Dermatology and numerous add-on acquisitions and the recapitalization of Pinnacle Dermatology Management by BayPine LP
• Quad-C Management in its investments in PRISM Vision Group, US Endo Partners and in the sale of VMG Health to Northlane Capital Partners
• REGENXBIO in its $1.8 billion strategic partnership with AbbVie to develop and commercialize RGX-314
• Summit Partners in transactions with AdvoServ, Covenant Surgical Partners, Patient Care Management,  and Abode Healthcare
• Spindletop Capital Management in its investments in San Antonio Pain Management and Sanova Dermatology
• Michelin in the auction and sale of a controlling interest in its US life sciences subsidiary, Solesis, Inc., to Altaris Capital Partners at a $475 million enterprise value
• Neurovance in its sale to Otsuka Pharmaceuticals
• Twelve Six Capital in the acquisition of Radial Health and its subsequent sale to IRC, a Webster Capital portfolio company
• G Square Capital, a London-based private equity fund, in its cross-border acquisition of a controlling interest in 3B Scientific
• Pouschine Cook Capital Management in the acquisition and sale of Golden State Dermatology Management, the acquisition of Southern Dental Alliance and its investment in Curexa Pharmacy
• Advent International, a global private equity fund, in the due diligence of inVentiv Health, Inc.
• Aligned Modern Health, a chiropractic physical medicine, acupuncture and functional medicine provider, in multiple financing rounds
• Alpine Investors in its investment in Summit Dermatology Partners and Midwest Vision Partners
• Calera Capital in its investment in United Dental Partners and Bay State Physical Therapy
• Equum Medical in its growth equity investment from Heritage Group
• Frazier Healthcare Partners in its formation of and investment in United Digestive
• H.I.G. Capital in the acquisition of Symbion, Inc., a national chain of ambulatory surgery centers by H.I.G. Capital portfolio company Surgery Partners
• Cleveland Clinic, Hospital for Special Surgery and Northwestern Medicine in a variety of strategic innovation investments and joint ventures
• Public Pension Capital (PPC) in its investment in Life Science Outsourcing, Inc.
• Physicians Medical Center, a physician-owned hospital, in its sale of a majority interest to SCA, an Optum/UnitedHealthcare Company (an American healthcare services provider)
• Surgical Institute of Reading in a strategic transaction with United Surgical Partners
• Wildcat Capital Management in its investment in Spring Fertility Management
• Multiple founder-owned businesses in strategic transactions with investors, including Spring Dental Management in the sale of a majority of its equity to Sorenson Capital and the sale of a controlling interest in Green Compass Global to an undisclosed investor

Show Less

• LMG Life Sciences, Life Sciences Star, 2016, 2018, 2019
• LMG Life Sciences’ 2015 “Collaboration Deal of the Year,” for representation of Baxalta in a global license and collaboration with Merrimack Pharmaceuticals
• The M&A Advisor, Top 40 Under 40 Legal Advisors 2015

Show Less